S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Ligand Pharmaceuticals Stock Forecast, Price & News

-3.75 (-2.62 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume110,628 shs
Average Volume332,247 shs
Market Capitalization$2.32 billion
P/E Ratio50.25
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ligand Pharmaceuticals logo

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.16 out of 5 stars

Medical Sector

383rd out of 1,352 stocks

Pharmaceutical Preparations Industry

187th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

Is Ligand Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ligand Pharmaceuticals?

Wall Street analysts have given Ligand Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ligand Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, October 29th 2021.
View our earnings forecast for Ligand Pharmaceuticals

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings data on Thursday, July, 29th. The biotechnology company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.15 by $0.48. The biotechnology company earned $84.68 million during the quarter, compared to analyst estimates of $73.32 million. Ligand Pharmaceuticals had a net margin of 19.03% and a trailing twelve-month return on equity of 9.47%. During the same period in the previous year, the business earned $1.00 EPS.
View Ligand Pharmaceuticals' earnings history

How has Ligand Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LGND stock has increased by 51.6% and is now trading at $139.18.
View which stocks have been most impacted by COVID-19

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of $5.800-$6.050 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.120. The company issued revenue guidance of $265 million-$275 million, compared to the consensus revenue estimate of $280.44 million.

What price target have analysts set for LGND?

5 equities research analysts have issued 1-year price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $180.00 to $310.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $223.75 in the next year. This suggests a possible upside of 60.8% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • John L. Higgins, Chief Executive Officer & Director
  • Matthew William Foehr, President & Chief Operating Officer
  • Matthew Edward Korenberg, Chief Financial Officer & Executive VP-Finance
  • Eric Vajda, Vice President-Preclinical Research & Development
  • Charles Stuart Berkman, Secretary, Senior Vice President & General Counsel

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.14%), William Blair Investment Management LLC (7.47%), Villere ST Denis J & Co. LLC (3.57%), Macquarie Group Ltd. (3.56%), Chicago Capital LLC (2.76%) and Conestoga Capital Advisors LLC (2.65%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, John L Higgins, Matthew W Foehr and Todd C Davis.
View institutional ownership trends for Ligand Pharmaceuticals

Which institutional investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Kornitzer Capital Management Inc. KS, Conestoga Capital Advisors LLC, Citadel Advisors LLC, Rice Hall James & Associates LLC, William Blair Investment Management LLC, Susquehanna International Group LLP, and HAP Trading LLC. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, John L Higgins, Matthew W Foehr, and Todd C Davis.
View insider buying and selling activity for Ligand Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ligand Pharmaceuticals stock?

LGND stock was purchased by a variety of institutional investors in the last quarter, including abrdn plc, Macquarie Group Ltd., Villere ST Denis J & Co. LLC, Murchinson Ltd., Federated Hermes Inc., Northern Trust Corp, Dimensional Fund Advisors LP, and Edgestream Partners L.P..
View insider buying and selling activity for Ligand Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $139.18.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals has a market capitalization of $2.32 billion and generates $186.42 million in revenue each year. The biotechnology company earns $-2,980,000.00 in net income (profit) each year or $3.13 on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

Ligand Pharmaceuticals employs 2,018 workers across the globe.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is www.ligand.com.

Where are Ligand Pharmaceuticals' headquarters?

Ligand Pharmaceuticals is headquartered at 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 550-7500 or via email at [email protected].

This page was last updated on 9/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.